Abbott Earnings Show Obesity Drug Worries Are Overblown

Wall Street has fallen into a repeating pattern this autumn: Strategists discover another sector that the obesity medicines from Eli Lilly and Novo Nordisk will supposedly decimate, and investors rush to sell. It has happened in packaged foods, medical devices, and restaurants, among others.

Investors had worried that the new obesity drugs, which are also approved to treat Type 2 diabetes, would eat away at sales of the Libre and other Abbott diabetes products. Ford said use of the Libre is actually complementary with the new obesity drugs, known as GLP-1 receptor agonists. In a note Thursday, Mizuho analyst Anthony Petrone wrote that uptake of the FreeStyle Libre in combination with GLP-1 drugs can sustain the Libre’s growth profile, “at least over the near-term.”

In other words, despite the enormous revenue potential for the GLP-1 drugs, the actual number of patients likely to take them in the foreseeable future isn’t actually so large, in the context of some of these markets.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Abbott Labs shares rise as company beats earnings estimates, raises full-year guidanceEleanor Laise is a healthcare reporter for MarketWatch and is based in Washington.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »

AI stole the show this year, but earnings will drag Wall Street back to realityCompanies are beefing up spending on their own AI capabilities, all while AI revenues largely have yet to materialize
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »